Aligos Therapeutics (NASDAQ:ALGS) Shares Up 5% - Should You Buy?

Key Points

• Aligos Therapeutics' shares rose 5% to $10.29, with a trading volume down 25% from the average daily volume.
• Wall Street analysts maintain a consensus Buy rating with a price target of $50.00, suggesting strong potential for future growth.
• The company reported a revenue of $0.97 million for the last quarter, exceeding analyst estimates and narrowing its loss per share to ($1.53).

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report)'s stock price was up 5% during mid-day trading on Wednesday . The company traded as high as $10.44 and last traded at $10.29. Approximately 49,337 shares traded hands during trading, a decline of 25% from the average daily volume of 65,705 shares. The stock had previously closed at $9.80.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Aligos Therapeutics in a report on Friday, September 12th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Aligos Therapeutics currently has a consensus rating of "Buy" and an average target price of $50.00.

Aligos Therapeutics Trading Up 5.0%

The business has a fifty day simple moving average of $9.41 and a two-hundred day simple moving average of $7.79. The stock has a market cap of $63.28 million, a PE ratio of -0.52 and a beta of 2.77.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, topping analysts' consensus estimates of ($2.35) by $0.82. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%.The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. On average, research analysts predict that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. boosted its position in shares of Aligos Therapeutics by 43.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company's stock worth $3,836,000 after purchasing an additional 140,000 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth approximately $3,399,000. Sio Capital Management LLC boosted its position in shares of Aligos Therapeutics by 85.9% in the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company's stock worth $2,422,000 after purchasing an additional 155,217 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth approximately $2,602,000. Finally, Heights Capital Management Inc. bought a new stake in shares of Aligos Therapeutics in the 1st quarter worth approximately $1,992,000. 60.43% of the stock is owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.